ArticleReports of biochemistry & molecular biology2025
Update on the Association of CD44 Expression with Esophageal Squamous Cell Carcinoma Invasion.
Article in Reports of biochemistry & molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal cancer (EC) is an aggressive gastrointestinal tumor necessitating novel prognostic, diagnostic, and therapeutic strategies. It is essential to identify important markers for diagnosing malignancy and predicting outcomes. Understanding gene functions in signaling pathways and early cancer detection are vital for reducing EC mortality. CD44 upregulation is linked to cancer stem cells (CSC), metastasis, poor prognosis, and treatment response. CD44v6, a variant of CD44, plays a pivotal role in tumor invasion and metastasis by influencing the extracellular matrix, promoting cell motility, and suppressing cancer cell apoptosis. Methods: This study investigated CD44v6 expression in tumor and tumor-free tissues of the esophagus in 50 esophageal squamous cells carcinomas (ESCC) patients using real-time PCR. The aim was to assess its prognostic value and its correlation with tumor invasion. Results: Significant overexpression of CD44v6 mRNA was detected in 9 out of 50 tumor specimens (18%, p = 0.0001). CD44v6 expression showed an inverse correlation with tumor cell metastasis to lymph nodes (p = 0.047). Among the 21 patients with lymph node metastasis, 5 (23%) exhibited CD44v6 overexpression. Additionally, CD44v6 expression was linked to the tumor stage (p = 0.008). Specifically, 2 out of 9 patients with stage I tumors (22.2%), 4 out of 9 with stage II tumors (44.4%), and 3 out of 9 with stage III tumors (33.3%) showed CD44v6 overexpression. Conclusions: Our findings suggest that lower CD44v6 expression at the RNA level correlates with increased tumor invasion and more advanced stages in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.